Chemical Inducers of Lineage Reprogramming Bypass Pluripotency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current direct lineage reprogramming methods face limitations in efficiency and functional maturity of induced cells, particularly in generating diverse cell types without going through the tumorigenic pluripotent stage, and achieving high cell yield.
Innovation Solution
The use of small molecule cocktails, specifically chemical inducers of lineage reprogramming (CiLR), including GSK inhibitors, TGFβ receptor inhibitors, cyclic AMP agonists, histone acetylator/deacetylase inhibitors, DOT1L methyltransferase inhibitors, retinoic acid receptor agonists, and histone demethylation inhibitors, to convert cells into a modified XEN-like state and subsequently into different lineages, bypassing pluripotency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If direct lineage reprogramming is performed using traditional methods, then cell fate transition is achieved, but reprogramming efficiency and functional maturity are limited
Solution Approach 1:
The patent applies parameter changes by systematically optimizing the concentrations and combinations of small molecules in the reprogramming cocktail. By adjusting parameters such as GSK3 inhibitor concentration, TGFβ inhibitor dosage, and cAMP agonist levels, the method achieves enhanced reprogramming efficiency and functional maturity while maintaining cell yield
Solution Approach 2:
The patent uses a composite approach by combining multiple small molecules into a synergistic cocktail formulation. This composite reprogramming system integrates GSK3 inhibitors, TGFβ inhibitors, cAMP agonists, and other compounds to achieve superior reprogramming outcomes that individual components cannot accomplish alone
2Adaptability or versatility
If transgenic approaches are used to induce lineage reprogramming, then cell-type-specific transcription factors can be introduced, but genome integration risk increases
Solution Approach 1:
The patent substitutes mechanical/genetic methods with chemical methods by replacing transgenic transcription factor delivery with small molecule compounds. This chemical reprogramming approach activates endogenous gene networks through epigenetic modulation and signaling pathway manipulation, achieving cell fate conversion without genome integration and eliminating tumorigenic risk
3Ease of operation
If chemical reprogramming is performed without optimized cocktails, then simplicity is maintained, but functional maturity of induced cells is reduced
Solution Approach 1:
The patent optimizes parameters including small molecule concentrations, treatment durations, and addition sequences to achieve functional maturity while preserving ease of operation. The optimized cocktail formulation requires only standard cell culture techniques, making the method accessible without compromising cell quality
Data Source
AI summary
Provided are chemical inducers of lineage reprogramming (CiLR) which include glycogen synthase kinase inhibitors, TGFβ receptor inhibitors, cyclic AMP agonists or histone acetylators. Also provided is a method of inducing lineage reprograming in a partially or completely differentiated cell of a first type into a cell with characteristics of a second and different lineage. The method includes: contacting a cell with the CiLR for a sufficient period of time to result in reprograming the cell into a modified XEN-like cell which is subsequently programmed into a cell with characteristics of a second and different lineage.